In April 2021 CLINUVEL announced its second Strategic Update, focussing on the decision processes underlying choices to expand and grow the Group of companies. A main goal of CLINUVEL’s growth is to integrate skills and functions in-house within the Group. To access the Strategic Update II microsite, go to https://www.clinuvel.com/strategic-update-home/ To learn more about the CLINUVEL Group, go to https://www.clinuvel.com

CBM Showreel - A brief intro to Clinuvel's Communications Branding & Marketing team

For decades, our Light Skin Science team have worked tirelessly to understand the damaging effects of light (UVA/UVB & HEV) on human health. Our quest now is to help reduce cases of skin cancer globally by sharing our 25 years of expertise with those at the highest risk. Find out more by visiting us: https://bit.ly/3mPB1jR

'Photo protection on a different wavelength.' 3D render generated to promote the launch of Cyacelle - a new generation in solar protection, designed for those at higher risk of exposure to harmful UV & HEV light.

Clinuvel hosts an evenings entertainment for investors showcasing international musicians and special guest speakers.

Understanding the effects of stroke and CLINUVEL’s pursuit to evaluate the safety and efficacy of afamelanotide in stroke patients with the greatest unmet medical need.

CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides an overview of results from the first clinical study of CLINUVEL’s drug afamelanotide in arterial ischaemic stroke (AIS) patients, then discusses the impact for patients’ lives and gives an update on the next steps in the clinical program for AIS.

Recording of CLINUVEL's 2022 Annual General Meeting, held on 26 October 2022.

Captured at the 2021 Morgans Scone Value in the Vines Conference, CLINUVEL's CEO Dr Philippe Wolgen discusses the culture of the CLINUVEL with Morgans Scone's Sam Paradice and Shaun Trewin.

On 14 February 2022, CLINUVEL announced the start of the second study in its DNA Repair Program, evaluating afamelanotide as skin DNA repair therapy. This mechanistic study (CUV151) will evaluate afamelanotide in disease-free adults. In this first of two videos after the announcement, CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses CLINUVEL’s focus on unmet clinical need and how this led to the DNA Repair Program and treating xeroderma pigmentosum (XP) patients. To read more about the DNA Repair Program, head to CLINUVEL’s website https://www.clinuvel.com.

In January 2022, CLINUVEL announced that it had completed enrolment in its world-first study of afamelanotide as a treatment for arterial ischaemic stroke (AIS) patients. Following this news, CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, provides background on the importance of safety data at the early stages of an innovative clinical program. To read more about the CUV801 program, head to CLINUVEL’s website (www.clinuvel.com).

An introduction to Medirest video was created to showcase all the services offered by Medirest to potential new B2B clients including; Patient Catering, Cleaning, Logistics, Support Services, Security & Retail. i.e. 'Keeping Your Hospital Moving 24/7'

Medirest Healthcare: 'Delivered With Heart' video was scripted, filmed and edited as part of a tender bid to showcase Medirest Services and to highlight the 'human' side of Medirest. This tender video was specifically aimed towards Maternity Hospitals.

As part of a tender for Four Seasons Health Care, we created this insight piece to demonstrate how Compass Group could provide a dedicated and cost efficient catering solution for all their Care Home needs.